Related Experiment Video
Updated: Feb 7, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study
Massimiliano Mirabella1, Luca Prosperini2,3, Matteo Lucchini4
1Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, 00168, Rome, Italy. massimiliano.mirabella@unicatt.it.
Background:
Two phase III trials have demonstrated the clinical and radiological efficacy of delayed-release dimethyl fumarate (DMF) in relapsing-remitting multiple sclerosis (RRMS). However, data on its safety and effectiveness in real-world practice are still limited.
Objectives:
The aim of our study was to explore the safety and tolerability profile of DMF in RRMS. We also tried to identify individual variables associated with better clinical and radiological outcomes.
Methods:
We collected the clinical and magnetic resonance imaging (MRI) data of patients with RRMS who started DMF between 2012 and 2017 in seven MS clinics in central Italy. We first evaluated DMF discontinuation rates and the incidence of adverse events and side effects. We then assessed the annualized relapse rate (ARR), the number of patients with clinical relapses or disability worsening and the presence of radiological activity. Third, we investigated which baseline variables were associated with clinical and radiological outcomes.
Results:
We collected data for 1089 patients with a mean on-treatment follow-up of 17 ± 8 months; 331 (30.4%) of these patients were treatment naïve. In total, 210 (19.5%) patients discontinued DMF mainly because of poor tolerability (n = 103) and disease activity (n = 63), and 166 (16.5%) patients presented with lymphopenia. The ARR reduced from 0.55 to 0.13. Mean change in Expanded Disability Status Scale (EDSS) score was 0.08 ± 0.44 per year. The occurrence of clinical and/or radiological activity during follow-up was associated with younger age [hazard ratio (HR) 0.97; p < 0.001], higher EDSS score (HR 1.18; p < 0.001), greater number of Gd-enhancing lesions at baseline scan (HR 1.14; p = 0.003) and prior exposure to MS treatments (HR 1.43; p = 0.02).
Conclusion:
This post-marketing data confirms the short-term safety, tolerability and effectiveness of DMF, supporting its use as an early treatment in MS.
Insights
Delayed-release dimethyl fumarate (DMF) shows good short-term safety and effectiveness in real-world relapsing-remitting multiple sclerosis (RRMS) patients. This supports its use as an early treatment option for MS.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Two Phase III trials confirmed the efficacy of delayed-release dimethyl fumarate (DMF) for relapsing-remitting multiple sclerosis (RRMS).
- Real-world data on the safety and effectiveness of DMF in RRMS are limited.
Purpose of the Study:
- To evaluate the safety and tolerability of DMF in RRMS patients in a real-world setting.
- To identify patient variables associated with improved clinical and radiological outcomes.
Main Methods:
- Collected clinical and MRI data from 1089 RRMS patients initiating DMF between 2012-2017 across seven Italian MS clinics.
- Assessed DMF discontinuation rates, adverse events, annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS) changes, and radiological activity.
- Investigated baseline variables linked to clinical and radiological outcomes.
Main Results:
- DMF discontinuation occurred in 19.5% of patients, primarily due to tolerability (103) and disease activity (63). Lymphopenia affected 16.5% of patients.
- ARR decreased from 0.55 to 0.13; mean EDSS change was +0.08 per year.
- Clinical/radiological activity was associated with younger age, higher baseline EDSS, more baseline Gd-enhancing lesions, and prior MS treatment exposure.
Conclusions:
- Real-world data confirm the short-term safety, tolerability, and effectiveness of DMF in RRMS.
- Findings support the use of DMF as an early treatment strategy for multiple sclerosis.
Related Concept Videos
Survey Safety
Bioavailability Study Design: Single Versus Multiple Dose Studies
Self-Efficacy
Multiple Allele Traits
Household Wiring And Electrical Safety
Case Studies

